Dataset Information

Identification of immunogenic LY6K long peptide encompassing both CD4⁺ and CD8⁺ T-cell epitopes and eliciting CD4⁺ T-cell immunity in patients with malignant disease.

ABSTRACT: Identification of peptides that activate both tumor-specific helper T (Th) cells and cytotoxic T lymphocytes (CTLs) are important for the induction of effective antitumor immune responses. We focused on a long peptide (LP) derived from lymphocyte antigen 6 complex locus K (LY6K) encompassing both candidate Th epitopes and a known CTL epitope. Using IFNγ ELISPOT assays as a marker of activated T cells, we studied the immunogenicity and cross-priming potential of LY6K-LP, assaying human immune cell responses in vitro and immunologic activities in HLA-A24 transgenic mice in vivo. We identified LY6K_172-191-LP as an effective immunogen spanning naturally processed epitopes recognized by T helper type 1 (Th1) cells and CTLs. LY6K-specific CTLs were induced through cross-presentation o

SUBMITTER: Tomita Y

PROVIDER: S-EPMC4203508 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature

ACCESS DATA

Dataset Information

Identification of immunogenic LY6K long peptide encompassing both CD4⁺ and CD8⁺ T-cell epitopes and eliciting CD4⁺ T-cell immunity in patients with malignant disease.

OmicsDI is part of the ELIXIR infrastructure

Tweets

Dataset Information

Identification of immunogenic LY6K long peptide encompassing both CD4+ and CD8+ T-cell epitopes and eliciting CD4+ T-cell immunity in patients with malignant disease.

OmicsDI is part of the ELIXIR infrastructure

Tweets

Identification of immunogenic LY6K long peptide encompassing both CD4⁺ and CD8⁺ T-cell epitopes and eliciting CD4⁺ T-cell immunity in patients with malignant disease.